Oncoptpeptides - Bring hope through science

Bringing hope through science

Monica Shaw CEO Oncopeptides

Monica Shaw appointed CEO

On January 4, 2023, Oncopeptides announced that the Board of Directors has appointed Dr Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer. These changes are effective immediately.

Read the press release

Jakob Lindberg interviewed by Di.TV

Jakob Lindberg interviewed by Di.TV regarding the leadership change

On Wednesday January 4, Jakob Lindberg was interviewed by by the Swedish economy TV channel Di.TV regarding the announced leadership change in Oncopeptides. Jakob Lindberg comments on his resignation as CEO of Oncopeptides and the appointment as Chief Scientific Officer.

See the interview on Di.TV (in Swedish)

Events Oncopeptides

Upcoming events

View calendar

Released

Interim report Q3 2022

”Oncopeptides enters a new phase with EMA approval and launch of Pepaxti in Germany as the first market”

CEO Jakob Lindberg

 

See the Webcast


For further information, please contact:

Rolf Gulliksen
Global Head of Corporate Communications

 

Year-end report 2022,
February 16, 2023

Profile image
Jakob Lindberg, CEO Oncopeptides.com

CEO Jakob Lindberg interviewed by Di.TV regarding the Q3 report and the EU and US market

On November 9, 2022, CEO Jakob Lindberg was interviewed by Börsmorgon in the Swedish Dagens Industri Di.TV regarding the Q3 report and the EU and US market. See the interview by clicking the link below. The interview is in Swedish.

To the interview in Di.TV

Tyska lanseringen av Pepaxti - presentation

Fredagen den 21 oktober kl.14.00, 2022, håller Oncopeptides en presskonferens för att prata om den tyska lanseringen av Pepaxti®.

Se presentationen i PDF här

Jakob Lindberg

European Commission approves Oncopeptides' Pepaxti

“The approval of Pepaxti in Europe is foundational for Oncopeptides, and brings excellent news for patients and shareholders,” says Jakob. “Despite the introduction of novel therapies, patients with triple class refractory disease have a high unmet medical need, since their treatment options ultimately become exhausted.”

Link to the press release

Webcast - CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU

June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU. 

Investors, financial analysts, and media were invited to participate in a webcast with a Q&A session on June 27, 2022, at 11:00 (CET). The event was hosted by CEO Jakob Lindberg, CMO Klaas Bakker and CFO Annika Muskantor. 

More info, presentation and the webcast link

Released

Annual Report 2021

Letter from the CEO - Science is leading the way

 

For further information, please contact:

Rolf Gulliksen
Global Head of Corporate Communications

Profile image
Jakob Lindberg, CEO

Letter from the CEO - Science is leading the way

"When I look back at 2021, this has been the most revolutionary year in Oncopeptides’ history"
Jakob Lindberg, CEO

Jakob interviewed by Di.TV - as new CEO about going forward

In conjunction with the anouncement of Jakob Lindberg as new CEO of Oncopeptides, he was interviewed by the Swedish economy TV channel Di.TV about the company's priorities going forward.

See the interview (Swedish) or read the transcript

Jakob Lindberg, CEO

Jakob Lindberg appointed CEO

On November 15, Oncopeptides announced that the Board of Directors has appointed Jakob Lindberg as Chief Executive Officer, CEO of Oncopeptides. Jakob Lindberg replaces Marty J Duvall, who has been the CEO since July 1, 2020. These changes are effective immediately.

Read the press release

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions. 
Read more

Oncopeptides vision

Vision of Oncopeptides

“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more